Genomic Evaluation of Multiparametric Magnetic Resonance Imaging-visible and -nonvisible Lesions in Clinically Localised Prostate Cancer by Parry, MA et al.
E U RO P E AN URO L OGY ONCO L OGY 2 ( 2 019 ) 1 – 11
ava i lable at www.sciencedirect .com
journa l homepage: euoncology.europeanurology.comEUO Priority Article – Prostate Cancer
Genomic Evaluation of Multiparametric Magnetic Resonance
Imaging-visible and -nonvisible Lesions in Clinically Localised
Prostate CancerMarina A. Parry a,b,1 2, Shambhavi Srivastava a,b,c,2, Adnan Ali b,d,e,2, Alessio Cannistraci a,b,2,
Jenny Antonello b,f, Joa˜o Diogo Barros-Silva b,e, Valentina Ubertini b,e, Vijay Ramani g,
Maurice Lau g, Jonathan Shanks h, Daisuke Nonaka h, Pedro Oliveira h, Thomas Hambrock i,
Hui Sun Leong c, Nathalie Dhomen a, Crispin Miller b,c,j, Ged Brady b,f, Caroline Dive b,f,
Noel W. Clarke b,d,g,k,3,*, Richard Marais a,b,3,*, Esther Baena b,e,3,*
aMolecular Oncology, Cancer Research UK Manchester Institute, The University of Manchester, Alderley Park, UK; bBelfast-Manchester Movember Centre of
Excellence, Cancer Research UKManchester Institute, The University of Manchester, Alderley Park, UK; cComputational Biology, Cancer Research UKManchester
Institute, TheUniversity ofManchester, Alderley Park, UK; dGenitourinary Cancer ResearchGroup, Division of Cancer Sciences, School ofMedical Sciences, Faculty
of Biology, Medicine & Health, The University of Manchester, Manchester Cancer Research Centre, Manchester, UK; eProstate Oncobiology, Cancer Research UK
Manchester Institute, The University of Manchester, Alderley Park, UK; fClinical and Experimental Pharmacology, Cancer Research UK Manchester Institute, The
University ofManchester, Alderley Park, UK; gDepartment of Surgery, The Christie NHS FoundationTrust,Manchester, UK; hDepartment of Pathology, The Christie
NHS Foundation Trust, Manchester, UK; iDepartment of Radiology, The Christie NHS Foundation Trust, Manchester, UK; jRNA Biology, Cancer Research UK
Manchester Institute, The University of Manchester, Alderley Park, UK; kDepartment of Urology, Salford NHS Foundation Trust, Salford, UKArticle info
Article history:










Background: The prostate cancer (PCa) diagnostic pathway is undergoing a radical
change with the introduction of multiparametric magnetic resonance imaging
(mpMRI), genomic testing, and different prostate biopsy techniques. It has been
proposed that these tests should be used in a sequential manner to optimise risk
stratification.
Objective: To characterise the genomic, epigenomic, and transcriptomic features of
mpMRI-visible and -nonvisible PCa in clinically localised disease.
Design, setting, and participants: Multicore analysis of fresh prostate tissue sam-
pled immediately after radical prostatectomy was performed for intermediate- to
high-risk PCa.
Intervention: Low-pass whole-genome, exome, methylation, and transcriptome
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areas in the same prostate. Circulating free and germline DNA was assessed from
the blood of ﬁve patients.
Outcome measurement and statistical analysis: Correlations between preopera-
tive mpMRI and genomic characteristics of tumour and benign prostate samples
were assessed. Gene proﬁles for individual tumour cores were correlated with
existing genomic classiﬁers currently used for prognostication.
Results and limitations: A total of 43 prostate cores (22 tumour and 21 benign)were
proﬁled from six whole prostate glands. Of the 22 tumour cores, 16 were tumours
visible and six were tumours nonvisible on mpMRI. Intratumour genomic, epige-
nomic, and transcriptomic heterogeneity was found within mpMRI-visible lesions.
This could potentially lead tomisclassiﬁcation of patients using signatures based on
copy number or RNA expression. Moreover, three of the six cores obtained from
mpMRI-nonvisible tumours harboured one or more genetic alterations commonly
observed in metastatic castration-resistant PCa. No circulating free DNA alterations
were found. Limitations include the small cohort size and lack of follow-up.
Conclusions: Our study supports the continued use of systematic prostate sam-
pling in addition to mpMRI, as avoidance of systematic biopsies in patients with
negative mpMRI may mean that clinically signiﬁcant tumours harbouring genetic
alterations commonly seen in metastatic PCa are missed. Furthermore, there is
inconsistency in individual genomics when genomic classiﬁers are applied.
Patient summary: Our study shows that tumour heterogeneity within prostate
tumours visible onmultiparametricmagnetic resonance imaging (mpMRI) can lead
to misclassiﬁcation of patients if only one core is used for genomic analysis. In
addition, some cancers that were missed by mpMRI had genomic aberrations that
are commonly seen in advanced metastatic prostate cancer. Avoiding biopsies in
mpMRI-negative cases may mean that such potentially lethal cancers are missed.
© 2018 The Authors. Published by Elsevier B.V. on behalf of European Association of
Urology. This is an open access article under the CC BY-NC-ND license (http://creati-
vecommons.org/licenses/by-nc-nd/4.0/).
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Systematic transrectal ultrasound (TRUS) biopsies are
associated with sampling, grading, and staging errors
[1,2]. To address this issue, two trials have now evaluated
multiparametric magnetic resonance imaging (mpMRI) for
target guidance to improve the diagnostic accuracy [3,4]. The
benefit suggested by these studies has increased prebiopsy
mpMRI inmenwith suspected prostate cancer (PCa),with up
to 50% of men now undergoing prebiopsy mpMRI in some
countries [5]. There are further calls to usempMRI as a triage
test and dispense with systematic biopsies altogether in
nearly one-quarter of the men who have negative mpMRI
[6,7]. These proposals are based on the notion that the
tumoursmissedbympMRIareof “lowrisk”, as themajorityof
them tend to be of low grade and <10 mm [4,8]. However,
approximately 10% of Gleason score (GS)7 PCas aremissed
by mpMRI, and may possibly be lethal [4].
In addition, uncertainty relating to metastatic potential in
GS 3 + 4 and 4 + 3 cancers, combined with the known
intraprostatic tumour heterogeneity, has led to the develop-
ment of genomic tests for better prognostication and
prediction of clinical progression. Their combined use with
mpMRI is now being proposed with mpMRI-guided biopsies
to improve risk stratification and avoid overtreatment [9–
11]. Therefore, a newdiagnostic pathway inwhichmpMRI and
genomic tests are used sequentially to guide PCamanagementis emerging [12]. Performing these tests in succession is
challenging considering the multifocal nature of PCa and
possible misclassifications due to intratumour heterogeneity.
This developing diagnostic sequence, which fundamen-
tally depends on a binary decision dictated by mpMRI to
trigger biopsies followed by genetic tests to augment risk
stratification, raises concerns. If genomic tests are to be used
widely, then the implications of intratumour heterogeneity
in mpMRI-visible tumours that are biopsied need to be
evaluatedmore comprehensively. Perhapsmore important is
the 10% or more potentially significant PCas that are missed
because they are not detected by mpMRI; the genomic
makeup of these cancers could provide insights into their
metastatic capacity and help in assessing their potential
lethality. To gain insights into these questions, we conducted
a study correlating genomics and mpMRI findings for men
undergoing radical prostatectomy to elucidate the genomic
characteristics of mpMRI-visible and -nonvisible tumours
and to assess the inter-relationship and reliability of
currently available genomic classifiers in this setting.
2. Patients and methods
2.1. Tissue collection
Informed consent for fresh prostate tissue collection was obtained
preoperatively from patients undergoing prostatectomy at The Christie
E U RO P E AN URO L OGY ONCO LOGY 2 ( 2 019 ) 1 – 11 3NHS Foundation Trust (MCRC biobanking protocol 16_RIMA_06). The
sampling protocol was adapted from Warren et al. [13]. Post-prostatec-
tomy, the prostate was inked and then serially sectioned from apex to
base. A slice 1 cm thick was obtained from the mid-prostate
(Supplementary Fig. 1A). This slice was randomly sampled via punch
biopsy to yield 8–12 cores, with core locations marked and photo-
graphed. The sampling was blinded to mpMRI. Each core was bisected
and one half was ﬂash-frozen (Supplementary Fig. 1). Frozen samples
were processed according to the following procedure. Specimens were
embedded in optimal cutting temperature compound and multiple
sections were taken along the vertical axis (Supplementary Fig. 1B).
Sections from the top,middle, and bottomof each corewere stainedwith
haemotoxylin and eosin (H&E) and submitted to pathological review. A
consultant pathologist reviewed the H&E slides, marked the tumour area
for the dissection process, and assigned a cellularity score (Supplemen-
tary Table 1) to evaluate tumour content. Marked tumour regions were
macrodissected for simultaneous DNA/RNA extraction (AllPrep kit;
Qiagen, Hilden, Germany). The remaining prostate tissue was ﬁxed for
routine histopathological reporting. PCa grading was according to the
International Society of Urological Pathology 2014 recommendations
[14]. Where possible (5/6 patients), whole blood was obtained before
surgery and germline DNA (Qiagen DNA blood extraction kit) and
circulating free DNA (cfDNA) were extracted.
2.2. mpMRI and pathology correlation
mpMRI scans were performed preoperatively as part of routine clinical
care. Scanswere performed using a 1.5-T Siemens Avanto or Area scanner
(Siemens,Munich, Germany), with the following acquisitionparameters:
T2, repetition time (TR) 3600–6500 and echo time (TE) 85–107; and
diffusion, TR 3500–5800 and TE 64–97. T1-weighted, T2-weighted
(T2W), and diffusion-weighted images were reviewed by a specialist
uroradiologist and were scored using Prostate Imaging-Reporting and
Data System version 2 (PIRADS v2) [15]. Lesions with no visible areas or
overall PIRADS v2 scores of 1 and 2 were assigned as nonvisible lesions,
while PIRADS v2 scores 3, 4, and 5 were assigned as visible lesions
(Supplementary Table 1).
mpMRI correlation to whole-mount histopathology was performed
by identifying the axial plane in T2W images corresponding to the
histopathology section fromwhich the coreswere obtained. The location
of each core was mapped on T2W axial scans and their visibility or
invisibility was determined.
2.3. Library preparation and sequencing
DNA libraries were prepared using an Accel-NGS 2S DNA Library kit
(Swift Biosciences, Ann Arbor, MI, USA). In brief, 200 ng of DNA was
fragmented to a target size of 200 bp using acoustic fragmentation
(Covaris, Woburn, MA, USA) according to the manufacturer’s protocol
consisting of end-repair, adaptor ligation, and polymerase chain reaction
(PCR) ampliﬁcation (6 cycles). Exome capture was subsequently
performed using SureSelect Exome V6 + COSMIC (Agilent Technologies,
Santa Clara, CA, USA) and 750 ng of inputmaterial. In brief, librarieswere
hybridised to probes for 16 h at 65 C and subjected to ten cycles of PCR
ampliﬁcation. Before sequencing, libraries were run on a Bioanalyser
(Agilent Technologies) and quantiﬁed using the Library Quantiﬁcation
Kit qPCR (Kapa Biosystems, Wilmington, MA, USA), and equimolar
library pools were sequenced on a MiSeq 600 cycle V3 or NextSeq Mid
output (2  150 cycles; Illumina, SanDiego, CA, USA) for low-passwhole-
genome sequencing, or a HiSeq (2  100 cycles; Illumina) for whole-
exome sequencing. RNA libraries were prepared using a Clontech
SMARTer Total RNA-seq kit (Takara Bio, Kusatsu, Japan) for cases 1 and 5,
and a SureSelect RNA Poly-A kit (Agilent Technologies) for the remaining
cases. Libraries were prepared according to the manufacturer’s protocol.All were quantiﬁed using a Library Quantiﬁcation Kit (Kapa Biosystems)
and sequenced using HiSeq (2  100 cycles; Illumina). The average
coverage obtained was 0.7 for low-read whole-genome sequencing for
copy number and 54 for whole-exome sequencing. Methylation
analysis was performed using an Illumina Methylation EPIC BeadChip
array (Euroﬁns Genomics, Louisville, KY, USA) with 250 ng of input DNA
(data accession numbers EGAS00001002767 and GSE101908).
2.4. Percentage genome aberration and gene expression–based
classifier scores
The percentage genome aberration (PGA) and a 31-locus genomic
classiﬁer were calculated using copy number aberration (CNA) data. PGA
was calculated by dividing the sum of all bases altered across the whole
genome by the total number of bases (3,137,144,693) in GRCh37 [16]. The
31-locus PGA was calculated by dividing the sum of all bases altered in
the previously reported prognostic 31 genes by the total number of bases
in these 31 genes [17].
We also generated scores based on the expression of 12 cancer genes
included in the OncotypeDX test (Genomic Health, Redwood City, CA,
USA) [18], 31 cell-cycle progression genes included in the Prolaris test
(Myriad Genetics, Salt Lake City, UT, USA) [19], and 19 of the 22 genes
included in the Decipher signature (GenomeDx, San Diego, CA, USA)
[20]. Three Decipher genes are not publicly available and were not
included in the analysis [20]. To expand our analysis, we also included
genes from the AR signalling pathway as previously described
[21,22]. These scores were calculated as a sum of the z-scores for genes
in the respective panels as previously described [23]. The z-score for
genes of interest in each core was calculated by subtracting the pooled
mean from the RNA sequencing (RNA-seq) expression value and dividing
by the pooled standard deviation.
Additional experimental details are available in the Supplementary
material.
3. Results
3.1. Correlating mpMRI to histopathology
A total of 43 cores were collected for six men with
intermediate- to high-risk PCa who underwent radical
prostatectomy (Table 1). Each core was microscopically
evaluated for tumour content and histopathological char-
acteristics. Of the 43 samples, 22 were classified as tumour
cores, whereas the remaining samples were classified as
benign; all tumour specimen characteristics are listed in
Supplementary Table 1.
Correlation of mpMRI to whole-mount histopathology
revealed that case 1 had two mpMRI-visible lesions and
case 2 had three. The lesions for case 1 were sampled using
two cores: both cores from one lesion were scored GS 4 + 3,
and the other two had GS 4 + 4 (Fig. 1A). The three lesions
for case 2 were sampled using five cores: one of the lesions
was scored GS 3 + 4, while cores from the other two scored
GS 3 + 3 (Fig. 1B).
Cases 3, 4, and 5 had pathologically identifiable lesions
that were not visible on mpMRI, in addition to lesions that
were.We obtained two cores from thempMRI-visible lesion
from case 3 (3#1 and 3#2) and these contained GS 4
+ 3 disease (Fig. 1C), but the core from the nonvisible lesion
contained few tumour cells and was not analysed further.
Case 4 also had one visible and one nonvisible lesion on
mpMRI (Fig.1D). Two of the five cores from the visible lesion
Table 1 – Baseline clinical and pathological characteristics for six patients who underwent radical prostatectomy for intermediate- or high-
risk prostate cancer
Case 1 Case 2 Case 3 Case 4 Case 5 Case 6
Age at surgery (yr) 59 66 66 66 70 54
PSA at diagnosis (ng/ml) 3 34 6.5 6.8 8 5.8
Prostatectomy Gleason score 4 + 4 4 + 3 4 + 4 4 + 3 4 + 4 4 + 3
Pathology stage pT3b pT3a pT3a pT3a pT3a pT2
Nodal status pNX pN0 pN0 pNX pN0 pNX
Nodes examined 0 8 1 0 15 0
Surgical margin Negative Positive
(focal-apical)
Negative Negative Negative Negative
Perineural invasion Yes Yes Yes Yes Yes No
Lymphovascular invasion Yes No Yes No No No
PSA = prostate-speciﬁc antigen.
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nonvisible lesion had GS 3 + 4. Case 5 had two visible and
two nonvisible lesions. Cores were obtained from three of
the lesions (one visible, two nonvisible; Fig. 1E). The core
from the mpMRI-visible lesion had GS 4 + 3, whereas the
two cores from the nonvisible lesions had GS 3 + 4 and 3
+ 3. Finally, case 6 had no mpMRI-visible lesions, but TRUS
biopsy detected GS 4 + 3 cancer. We sampled two lesions, a
core with GS 4 + 3 and one with GS 3 + 3 (Fig. 1F). Thus,
while most of the high-grade (GS  4 + 3) and low-grade
tumours (GS 3 + 3) were visible on mpMRI, some clinically
relevant lesions were not detected (case 5#3 and case 6#5;
Supplementary Table 1).
3.2. Copy number landscape of mpMRI-visible and -nonvisible
lesions
We performed comprehensive genomic profiling to deter-
mine genomic changes in our samples. Germline DNA from
blood was used as a reference for all samples with the
exception of case 3, for whom DNA was extracted from a
histologically benign area of the prostate.
We first assessed CNA in the tumour cores. Consistent
with previous studies, CNA analysis (Fig. 2) revealed high
inter- and intrapatient heterogeneity associated with
variable PGA (range 0–11.1%, Supplementary material).
Cores obtained from mpMRI-visible lesions had a nonsig-
nificantly higher PGA (median 3.16%) compared to non-
visible lesions (median 0.4%; p = 0.0840, Mann-Whitney
test; Supplementary Fig. 2). Overall, chromosomal losses
were more prevalent than gains and included deletions in
chromosomes 8p (59%), 6q (45%), and 13q (41%), with the
regions affected spanning genes commonly associated with
PCa, such as NKX3.1, RB1, and BRCA2. Evidence of chromo-
thripsis was observed in chromosome 1 for both tumour
cores from case 3. As expected, cores with no CNA were
correlated with low GS. Owing to the relatively small
number of samples, wewere not able to single out a specific
CNA pattern for mpMRI-nonvisible tumours; however, we
did find significant structural aberrations in those cores
(Figs. 2 and 3). For example, case 5#3 (GS 3 + 4) had
deletions in known PCa-related tumour suppressors, such
asMAP3K7 [24,25] and FOXO3 [26], aswell as genes involved
in DNA repair pathways, such as MSH3, ERCC8, and RPC1(Supplementary material). Case 6#5 (GS 4 + 3) had dele-
tions in RB1, TP53, and BRCA2 loci, MYC amplification, and
TMPRSS2-ERG fusion (Figs. 2 and 3, Supplementary Fig. 3,
Supplementary Table 2). For all the patients fromwhomwe
collected blood, we did not identify CNA in cfDNA derived
from blood (Supplementary Fig. 4).
3.3. Mutational profile of mpMRI-visible and -nonvisible
tumours
Marked tumour heterogeneity was also found at the level of
individual somatic alterations. The number of somatic
mutations varied from 104 to 182 per tumour core, with an
average of 51 single-nucleotide variations per core (range
33–68) affecting exonic regions and, consequently, more
likely to cause amino acid changes. SPOP mutations were
found in tumour cores from four out of six patients (67%
patients; 27% total tumour cores). Intriguingly, all the
tumour cores from case 1 had alterations in the SPOPMATH
domain [27], however, cores 1#1 and 1#2 had a missense
mutation in the resulting amino acid K129E, while cores
1#5 and 1#6 in the amino acid F102 C (Fig. 3 and
Supplementary material), suggesting the presence of
parallel evolution. A single frameshift mutation in the
TP53 gene was identified in one nonvisible core (case 6#5),
while mutations in genes previously reported as commonly
altered in PCa, such as IDH1, FOXA1, and MED12 [28,29],
were not detected.
3.4. Gene expression and DNA methylation analysis
To assess the impact of tumour heterogeneity on gene
expression, we performed RNA-seq analysis for tumour and
benign cores from each patient in our cohort. First, principal
component analysis was applied to gene expression data to
identify grouping patterns for the samples. As shown in
Supplementary Figure 5, benign cores, with the exception of
a few cases, tended to cluster together and away from
tumour specimens. Conversely, tumour samples exhibited
more heterogeneous behaviour, with a trend towards
clustering together, probably as a reflection of their spatial
proximity in the gland. Next, we interrogated our samples
for the expression of a subset of genes from commercially
available genetic tests [18–22] that are increasingly used to
[(Fig._1)TD$FIG]
Fig. 1 – Correlation between histological characteristics and visibility on multiparametric magnetic resonance imaging. Haematoxylin and eosin (H&E)
whole-mount sections and corresponding axial T2-weighted image (T2WI) and apparent diffusion coefficient (ADC) maps for (A–F) cases 1–6. Tumour
areas are marked with a dotted line on H&E stains and indicated by red arrows on T2WI and ADC maps. Tumour cores are numbered and labelled with
colours; benign cores are labelled in grey.
E U RO P E AN URO L OGY ONCO LOGY 2 ( 2 019 ) 1 – 11 5
[(Fig._2)TD$FIG]
Fig. 2 – Copy number alteration profiles for cases 1–6. Copy number heatmap showing chromosomal losses (blue) and amplifications (red) for all cases.
The Gleason score and multiparametric magnetic resonance imaging (mpMRI) visibility for each of the tumour cores are also indicated and described
in the legends.
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scores were arbitrarily generated and applied to our cohort
for core stratification (Supplementary material). We found
little correlation in core ranking among the different
signatures, with tumours clustering together or away from
each other based on the genes taken into account for the
analysis, rather than mpMRI visibility (Fig. 4A). Similar
results were observed when we performed unsupervised
clustering of the samples (Fig. 4B).
Given the high variability observed in gene expression,
we performed methylation analysis to capture epigenetic
changes occurring in our cohort of patients. Unsupervised
clustering of tissue cores using the top 5000 variable CpG
values revealed clear separation between benign and
tumour samples, with the exception of case 2#3 and case
4#5 (Fig. 5A). Interestingly, the same trend was observed
when multidimensional scaling analysis was used (Supple-
mentary Fig. 6), suggesting that the molecular pressure
exerted by cancerous lesions on the surrounding normal
epithelium, a phenomenon described as the cancer-
proximity field effect or field cancerisation [30,31], was
limited in our cohort. Finally, we looked at the specific
methylation status of GSTP1, APC, and RASSF1, which have
recently been proposed as a three-gene methylation
signature to identify the presence of PCa lesions when
obvious histopathological confirmation is not available[32]. As shown in Figure 5B, benign cores separated from
tumour specimens when GSTP1 and APC were analysed,
while this effect was less pronounced for RASSF1. This
confirmed, at least in our cohort, that the identification of
clinically relevant tumours relies on the sampling accuracy.
4. Discussion
In this studywe used an integratedmpMRI-histopathology-
genomics approach to assess evolving methods for PCa
diagnosis and risk stratification. We found that intratumour
heterogeneity within mpMRI-visible lesion carries a risk of
patient misclassification when using genomic biomarkers
from a single biopsy. Moreover, dispensing with systematic
biopsies in mpMRI-negative cases can lead to failure to
detect potentially significant PCa harbouring genomic
alterations that are common in metastatic disease.
Our findings are in agreement with previous studies
demonstrating spatial genomic heterogeneity in localised
PCa [33–35]. The implications of intratumour heterogeneity
in using a single biopsy for genomic-based prognostication
or prediction have also been highlighted previously
[23,36]. Our study extends the findings to mpMRI-visible
tumours and evaluates the relevance of current genomic
testing in combination with mpMRI-guided tissue acquisi-
tion. For instance, consider a previously validated PGA
[(Fig._3)TD$FIG]
Fig. 3 – Integrative landscape analysis of somatic and copy number aberrations in tumour samples obtained from cases 1–6. Columns represent
individual tumour cores from each patient included in the analysis, and rows represent specific genes grouped in pathways. Specific chromosomal
aberrations and somatic alterations are described in the colour legends, together with Gleason score and magnetic resonance imaging (mpMRI)
characteristics. Cases with more aberrations in a gene are represented by split colours. Cores are colour-coded according to Figure 1.
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adjusted hazard ratio of 3.2–4.5 for predicting relapse
following radiotherapy or radical prostatectomy [37]. Then
of the two cores obtained from the same visible lesion, one
of the cores can classify the patient as low risk (case 1#6,
PGA 7.2%) while the other core can classify the patient as
high risk (case 1#5, PGA 11.1%). Similarly, intratumour
transcriptomic heterogeneity within mpMRI-visible lesions
can possibly lead tomisclassification using RNA-based tests.
As a result, patients can be misclassified using genomic
analysis based on a single mpMRI-targeted biopsy.
These findings have implications for management decisions
made on the basis of genomic tests from a single biopsy
[9–11,38–40].
Avoiding systematic biopsies in patients with negative
mpMRI is a strategy with significant risk. While there are a
range of options for consideration, the emerging enthusi-
asm for proceeding without biopsy on the basis of an
argument that tumours missed by mpMRI can be regarded
as “low risk” [8] may be misguided. This approach will
expose patients to the risk of misclassification of clinically
significant nonvisible tumours. Our study shows that PCa
tumours undetected by mpMRI can harbour genomic
alterations that are commonly seen in metastatic castra-
tion-resistant PCa (mCRPC) [41,42]. Using our mpMRI-blind
sampling approach, we collected six mpMRI-nonvisible
cores from three patients, three of which had one or more
genomic aberrations commonly associated with aggressive
biology and mCRPC. While two of these patients had other
mpMRI-visible lesions, case 6 had a negative mpMRI. This
patient had GS 4 + 3 (case 6#5) cancer with copy number
changes including RB1 and TP53 loss, as well as MYCamplification, which are commonly seen in mCRPC
[42]. This shows that mpMRI-nonvisible tumours could
be regarded as genomically aggressive and could potentially
give rise to lethal clones. Moreover, previous studies have
reported the presence of genomic alterations in histomor-
phologically benign prostate that could provide a backdrop
against which PCa develops from benign prostate glands
[34]. These findings based on “cancer field effect” are
relevant in cases with false-negative mpMRI, for whom
histologically benign biopsies could be used to predict
occult PCa [30,43]. Two studies, MATLOC and DOCUMENT,
have evaluated this approach in benign biopsies using a
methylation-based test to predict adverse pathology
[32,44]. However, we did not observe a consistent cancer-
field effect at the epigenetic level, again suggesting that
molecular evaluation of a single benign biopsy may be
insufficient to predict occult clinically significant PCa.
Our study has inherent limitations. The co-registration of
histopathology and mpMRI was performed cognitively, so
some tumours might have beenmissed. However, using our
single-slice protocol we captured the index tumour in all six
patients. Tighter spatial correlation can be attempted when
designing future studies using three-dimensional prostate
moulds with guides corresponding to mpMRI slice thick-
ness and scanning orientation to improve precision
[45,46]. Another shortcoming is the relatively small number
of patients and short-term follow-up. However, detailed
studies such as this are both time-consuming and expen-
sive, and it would be difficult to validate our findings on a
large scale and include long-term natural history. We also
used derived RNA-based expression scores rather than
commercial tests. While the proprietary algorithms used by
[(Fig._4)TD$FIG]
Fig. 4 – Gene expression analysis and classification of tumour cores. (A) Tumour core ranking based on expression-derived scores arbitrarily generated using normalised RNA sequencing values for all the
genes included in the OncotypeDX, Prolaris, and Decipher prognostic signatures. AR activity and percentage genomic aberration (PGA) scores were also calculated and included in the analysis. (B)




































Fig. 5 – Methylation analysis of prostate specimens from cases 1–6. Tissue types from each individual are colour coded as green (benign) and red
(tumour). (A) Unsupervised hierarchical clustering of methylation patterns for tumour and benign cores from cases 1–6. Rows of the heatmaps display
the b values for the top 5000 CpG sites with the greatest intrapatient DNA methylation variability. Blue indicates low and yellow represents high
methylation level (from 0 to 1). (B) Methylation array–derived b values for APC, GSTP1, and RASSF1 in benign and tumour cores.
E U RO P E AN URO L OGY ONCO LOGY 2 ( 2 019 ) 1 – 11 9these tests are not publicly available, results supporting our
findings have been published previously [23]. Another
study comparing the results of the commercial Decipher
test suggested that approximately one in five patients
could be potentially misclassified using mpMRI-targeted
biopsies [9].5. Conclusions
Our study emphasises the diagnostic complexities for
clinically localised PCa. Importantly, it highlights the
shortcomings of the new diagnostic method that uses
mpMRI on its own as a triage test and avoids systematic
samplingwhen visible lesions are present and avoids biopsy
when they are not. This clearly carries a risk of missing
potentially aggressive lesions that is not mitigated by the
use of current genomic classifiers. A single targeted biopsy
does not eliminate the problem of intraprostatic heteroge-
neity and the results obtained using this approach should be
interpreted with care to minimise the possibility of disease
misclassification.
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